Palifermin does not influence the incidence and severity of GvHD nor long-term survival of patients with hematological diseases undergoing HSCT

Barbara Nasilowska-Adamska; Richard Szydlo; Piotr Rzepecki; Anna Czyz; Agnieszka Tomaszewska; Miroslaw Markiewicz; Tigran Torosian; Maria Bieniaszewska; Andrzej Hellman; Wieslaw Wiktor Jedrzejczak; Jerzy Holowiecki; Mieczyslaw Komarnicki; Krzysztof Warzocha; Bozena Marianska

30 December 2011

Palifermin does not influence the incidence and severity of GvHD nor long-term survival of patients with hematological diseases undergoing HSCT

Barbara Nasilowska-Adamska^AEF, Richard Szydlo^C, Piotr Rzepecki^B, Anna Czyz^B, Agnieszka Tomaszewska^BD, Miroslaw Markiewicz^B, Tigran Torosian^B, Maria Bieniaszewska^B, Andrzej Hellman^D, Wieslaw Wiktor Jedrzejczak^D, Jerzy Holowiecki^D, Mieczyslaw Komarnicki^D, Krzysztof Warzocha^DE, Bozena Marianska^DE

Ann Transplant 2011; 16(4): 47-54 :: ID: 882218

Authors information Article notes Copyright and License information